Green light for small cell lung cancer treatment given to AstraZeneca in China

Based on positive results in a phase III trial, Imfinzi demonstrated improvement over chemotherapy alone, the approval was granted

AstraZeneca PLC, LON:AZN announced that Imfinzi was approved in China as a first-line treatment for adult patients with advanced-stage small-cell lung cancer (ES-SCLC).

It can be used together with standard of care platinum chemotherapy.

Positive results from a phase 3 trial that showed a statistically significant improvement in overall survival over chemotherapy alone were the basis for approval. The results of the China cohort of patients were also consistent with the global results.

According to FTSE 100, SCLC is a very aggressive and fast-growing type of lung cancer. It can recur and progress quickly despite initial treatment.

The prognosis for SCLC patients is poor. Only 7% and 3% of SCLC patients will live five years after diagnosis.

Dave Fredrickson (executive vice president, oncology business unit) stated that today’s approval for Imfinzi plus chemotherapy provides a global standard of care for patients suffering from advanced-stage small cell lung carcinoma in China. These patients have had limited treatment options and a grim prognosis.

“Physicians are now able to offer these patients an effective immunotherapy regimen that is well-tolerated and has a sustained overall survival rate, prolonged treatment response, and convenient dosing. Physicians will also be able to mix immunotherapy with cisplatin for the first time in China.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.